Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models

Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models

E7080, known as lenvatinib, is an oral multitargeted tyrosine kinase inhibitor that has been shown to improve the survival rate of patients with radioiodine-refractory thyroid cancer. However, a majority of patients do not continue lenvatinib intake due to disease progression or significant toxicity...

Full description

Bibliographic Details
Main Authors: Keisuke Enomoto, Shun Hirayama, Naoko Kumashiro, Xuefeng Jing, Takahito Kimura, Shunji Tamagawa, Ibu Matsuzaki, Shin-Ichi Murata, Muneki Hotomi
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Cancers
Subjects:
lenvatinib
E7080
selumetinib
AZD6244
combination therapy
thyroid cancer
Online Access:https://www.mdpi.com/2072-6694/13/4/862

Internet

https://www.mdpi.com/2072-6694/13/4/862

Similar Items